Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products.

Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change.

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations.

This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.

As a massive federal hammer prepares to fall on the hemp industry, progressive states are throwing operators a regulatory lifeline—just as the legal cannabis market faces its own "Big Tobacco" reckoning.

A newly filed federal class-action lawsuit targets major Chicago-based operators like Cresco Labs and Green Thumb Industries, accusing them of "Big Tobacco"-style deceptive marketing that downplays the psychotropic risks of high-THC products.

Yet, against this turbulent backdrop, Midwestern lawmakers are aggressively reshaping the market. Facing a looming November 2026 federal ban on potent hemp products, Minnesota has enacted a landmark omnibus bill that allows hemp business owners to dual-license and pivot directly into the regulated cannabis market.

Similarly, Illinois lawmakers are advancing a massive industry overhaul (HB 5784) designed to ease financial burdens on smaller social equity operators while building parallel transitional pathways for hemp companies. By allowing these industries to consolidate, states are creating a vital legal gateway for hemp businesses to survive under the umbrella of the regulated cannabis market before federal workarounds vanish entirely.

Blunt Business zeroes in on major developments unfolding on the congressional front. It highlights how impending federal rescheduling could significantly alter medical cannabis policies within the Veterans Administration, potentially expanding access for military veterans by allowing VA doctors to discuss and document use, as well as refer patients to state-approved programs.

Additionally, we break down the bipartisan BUILD Act (Building Unrivaled Infrastructure and Long-Term Development Act), a piece of transportation legislation moving toward a House floor vote. The bill directives mandate federal agencies to invest $110 million to research poly-substance impairment and establish standardized, evidence-based driving limits, addressing the long-standing scientific flaws and regional inconsistencies currently plaguing roadside testing.

This week on Blunt Business, we’re diving into two massive legal shifts reshaping cannabis markets on opposite sides of the country. First, we break down Georgia’s major policy overhaul as Governor Brian Kemp signs the "Putting Georgia's Patients First Act."From expanding the list of qualifying conditions to include lupus, to lifting strict "end-stage" limitations and allowing adult vaping and edibles, the Peach State is dramatically widening medical access.

Then, we pivot to Washington, D.C., where a high-stakes federal lawsuit challenging the District's cannabis licensing and enforcement system was suddenly dropped. We’ll analyze why the Alliance for Recreational Cannabis Entities voluntarily dismissed their case, how a recent federal appeals court ruling regarding the Dormant Commerce Clause triggered the move, and what this unresolved constitutional battle means for local market protections across the United States.

As the federal government moves toward rescheduling marijuana, the cannabis industry is eyeing a massive financial shift: the potential for $15 billion in retroactive tax relief from Section 280E. While the transition to Schedule 3 offers a path to future profitability, businesses must act immediately to file protective claims before statutes of limitation expire.

This economic evolution coincides with a significant demographic pivot, as older adults become the fastest-growing consumer group, frequently choosing edibles for pain and sleep management over pharmaceuticals.

However, the move toward higher-potency THC products is a double-edged sword, with new studies linking high-strength medicinal cannabis to increased risks of anxiety and psychiatric side effects, underscoring the need for careful regulation and informed medical guidance.

The potential move to Schedule III presents a massive financial opportunity for "Sin City," yet current local friction threatens to stall that momentum. As the federal government nears reclassification, the industry is at a crossroads between record-breaking growth and a cooling tourist market.

While the city is built on "cashing in," Las Vegas could be losing tourists due to a recent crackdown on public consumption and strict enforcement. For the city to fully capitalize on the "Green Rush," it must reconcile its status as a global playground with the reality of a regulated cannabis market. If tourists feel penalized for legal use, they may take their gambling and entertainment dollars elsewhere.

The shift to Schedule III is the "jackpot" many operators have been waiting for, primarily due to the removal of the 280E tax penalty. This change would allow businesses to finally treat cannabis like a standard industry, potentially injecting millions back into the local economy.

This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders.

The newly signed executive order to direct the FDA to fast-track these compounds through new "National Priority" vouchers.

Beyond psychedelics, the host discusses the impact of GLP-1 weight-loss drugs (like Ozempic) on the cannabis market, noting that dispensaries are seeing a shift in consumer preference toward lower-dose products to mitigate "the munchies."